v3.26.1
LICENSING AGREEMENTS AND ACQUISITIONS - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2025
USD ($)
Nov. 30, 2025
USD ($)
acquisition
Sep. 30, 2025
USD ($)
Jan. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Dec. 31, 2024
USD ($)
Business Combination [Line Items]              
Goodwill $ 11,271       $ 11,271 $ 9,793 $ 11,087
DURECT Corporation              
Business Combination [Line Items]              
Asset acquisition, consideration transferred     $ 84        
Payments to acquire productive assets     64        
Asset acquisition, recognized liabilities assumed     11        
Asset acquisition, consideration transferred, transaction cost     9        
Asset, contingent consideration     350        
Acquired IPR&D costs     81        
Asset acquisition, recognized assets acquired     $ 3        
Surgical Manufacturing Facility              
Business Combination [Line Items]              
Asset, contingent consideration 35       35    
Surgical Manufacturing Facility | Bausch + Lomb              
Business Combination [Line Items]              
Payments to acquire productive assets 75            
Shibo Zhenmei              
Business Combination [Line Items]              
Aggregate purchase consideration 87            
Estimated fair value of contingent consideration 17       17    
Contingent consideration, liability $ 3       3    
Estimated useful life of acquired intangible assets 15 months            
Goodwill $ 22       22    
Cash consideration paid $ 84            
Other Bausch + Lomb Acquisitions              
Business Combination [Line Items]              
Aggregate purchase consideration   $ 33          
Number of business acquisitions | acquisition   2          
Goodwill   $ 30          
Whitecap Biosciences Acquisition | Bausch + Lomb              
Business Combination [Line Items]              
Cash consideration paid       $ 28      
Expensed upfront payment of acquired IPR&D costs         $ 28